These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
767 related articles for article (PubMed ID: 27880667)
1. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). Lortholary O; Fernández-Ruiz M; Perfect JR J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667 [TBL] [Abstract][Full Text] [Related]
2. Changes in the epidemiological landscape of invasive mould infections and disease. Lass-Flörl C; Cuenca-Estrella M J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i5-i11. PubMed ID: 28355462 [TBL] [Abstract][Full Text] [Related]
3. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia. Schmiedel Y; Zimmerli S Swiss Med Wkly; 2016; 146():w14281. PubMed ID: 26901377 [TBL] [Abstract][Full Text] [Related]
4. How We Approach Combination Antifungal Therapy for Invasive Aspergillosis and Mucormycosis in Transplant Recipients. Haidar G; Singh N Transplantation; 2018 Nov; 102(11):1815-1823. PubMed ID: 29975240 [TBL] [Abstract][Full Text] [Related]
5. 2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan. Kung HC; Huang PY; Chen WT; Ko BS; Chen YC; Chang SC; Chuang YC; ; ; ; J Microbiol Immunol Infect; 2018 Feb; 51(1):1-17. PubMed ID: 28781150 [TBL] [Abstract][Full Text] [Related]
6. Defining standards of CARE for invasive fungal diseases in solid organ transplant patients. Garcia-Vidal C; Carratalà J; Lortholary O J Antimicrob Chemother; 2019 Mar; 74(Suppl 2):ii16-ii20. PubMed ID: 31222312 [TBL] [Abstract][Full Text] [Related]
7. Invasive mould infections in the ICU setting: complexities and solutions. Bassetti M; Bouza E J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i39-i47. PubMed ID: 28355466 [TBL] [Abstract][Full Text] [Related]
8. Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ruhnke M; Cornely OA; Schmidt-Hieber M; Alakel N; Boell B; Buchheidt D; Christopeit M; Hasenkamp J; Heinz WJ; Hentrich M; Karthaus M; Koldehoff M; Maschmeyer G; Panse J; Penack O; Schleicher J; Teschner D; Ullmann AJ; Vehreschild M; von Lilienfeld-Toal M; Weissinger F; Schwartz S Mycoses; 2020 Jul; 63(7):653-682. PubMed ID: 32236989 [TBL] [Abstract][Full Text] [Related]
9. Early diagnosis of invasive mould infections and disease. Lamoth F; Calandra T J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i19-i28. PubMed ID: 28355464 [TBL] [Abstract][Full Text] [Related]
10. [State of the art in invasive diseases by filamentous fungi]. Pemán J; Quindós G Rev Iberoam Micol; 2014; 31(4):213-8. PubMed ID: 25449676 [TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia. Fung M; Kim J; Marty FM; Schwarzinger M; Koo S PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923 [TBL] [Abstract][Full Text] [Related]
12. Breakthrough invasive mould infections in patients treated with caspofungin. Pang KA; Godet C; Fekkar A; Scholler J; Nivoix Y; Letscher-Bru V; Massias L; Kauffmann-Lacroix C; Elsendoorn A; Uzunov M; Datry A; Herbrecht R J Infect; 2012 Apr; 64(4):424-9. PubMed ID: 22227384 [TBL] [Abstract][Full Text] [Related]
13. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857 [TBL] [Abstract][Full Text] [Related]